Gallium Ga 68 dotatate is a radioactive imaging agent built on a small somatostatin-like peptide. The peptide homes in on somatostatin receptors, and the gallium-68 lets a PET scanner see where it lands. This guide covers its structure, mechanism, approval, studies and label warnings, with sources checked on November 17, 2026.
Quick answer: Gallium Ga 68 dotatate is a prescription PET imaging agent. Its label covers locating somatostatin receptor positive neuroendocrine tumors in adults and children. It is a diagnostic agent, not a treatment. It has no boxed warning. Label warnings cover radiation exposure, allergic reactions and the risk of misreading images.
Vitrapep does not sell gallium Ga 68 dotatate; this page is a reference summary of published research and regulatory information.
What is gallium Ga 68 dotatate?
The molecule has three parts. The first is a short peptide that targets tumors. The second is a chelator, a cage-like molecule that grips a metal atom. The third is the radioactive metal gallium-68, which gives off the signal a PET scanner detects.
The NETSPOT label states that dotatate, “also known as DOTA-0-Tyr3-Octreotate, is a cyclic 8 amino acid peptide with a covalently bound chelator (dota).” It gives the sequence as H-D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-OH and a molecular weight of 1,435.6 daltons for dotatate (NETSPOT label, 2023). The same peptide and chelator form the core of Lutathera, whose label calls it “a radiolabeled somatostatin analog” (Lutathera label, 2024).
It counts as a peptide because its targeting part is a chain of amino acids, including two D-amino acids. PubChem lists the gallium-68 complex as C65H87GaN14O19S2, with a molecular weight of 1,500.5 g/mol (PubChem CID 131634491). Our guide to types of peptides covers cyclic peptides. Drugs@FDA lists the original approval of NETSPOT on June 1, 2016, under NDA 208547, now held by Novartis (Drugs@FDA).
Gallium Ga 68 dotatate: key facts
| Fact | Detail |
|---|---|
| Structure type | Cyclic 8 amino acid peptide (Tyr3-octreotate) with a DOTA chelator holding gallium-68 |
| Class | Radioactive diagnostic agent; somatostatin receptor imaging agent |
| Molecular formula | C65H87GaN14O19S2 (gallium-68 complex, PubChem) |
| Molecular weight | 1,500.5 g/mol (complex, PubChem); dotatate alone 1,435.6 daltons (label) |
| First FDA approval | June 1, 2016 (NETSPOT, NDA 208547) |
| Brand names (US) | NETSPOT |
How does gallium Ga 68 dotatate work?
The agent targets tumors that are somatostatin receptor positive, the group named in its label. The NETSPOT label states that gallium Ga 68 dotatate “binds to somatostatin receptors, with highest affinity for subtype 2 receptors (SSTR2).” Once bound, the gallium-68 signal shows up on a PET scan.
The label also explains what the image means. “The uptake of gallium Ga 68 dotatate reflects the level of somatostatin receptor density in NETs” (NETSPOT label, 2023). So a bright spot marks tissue rich in these receptors. The same receptor target underlies the drugs in our octreotide and lanreotide guides.
What is gallium Ga 68 dotatate approved for?
The NETSPOT label has one indication, which applies once the product is labeled with gallium-68 (NETSPOT label, 2023). It “is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.”
Localization means finding where tumors are. Neuroendocrine tumors arise from hormone-producing cells. A related agent, Detectnet (copper Cu 64 dotatate), was approved in 2020 for the same imaging purpose in adults (Detectnet label, 2025).
What did the key studies show?
Vanderbilt study. The NETSPOT label rests on three open-label, single-center human studies. In Study A, 97 adults were evaluated. Gallium Ga 68 dotatate PET agreed with CT or MRI in 74 patients. It was positive in 48 of 50 patients whose tumors CT or MRI had found. It was negative in 26 of 28 patients whose CT or MRI was negative.
The published report of this study compared the agent with an older scan, indium-111 pentetreotide, in 78 of the 97 patients. Gallium Ga 68 dotatate PET was equivalent or superior in all 78. Combined with CT or liver MRI, it changed care in 28 of 78 patients (36%) (Deppen et al., 2016a). The registry record is NCT01396382.
Other label studies. Study B was a published study of 104 patients. The scan correctly found a tumor site in 29, was falsely negative in 7, negative in 61 and falsely positive in 7. Study C involved 63 patients read by two independent readers (NETSPOT label, 2023).
Meta-analysis. A systematic review pooled 42 eligible human studies. It estimated sensitivity at 90.9% (95% CI, 81.4% to 96.4%) and specificity at 90.6% (95% CI, 77.8% to 96.1%) (Deppen et al., 2016b).
What side effects does the label list?
The NETSPOT label has no boxed warning. Its safety data come from three single-center studies, and the label states: “No serious adverse reactions were identified.” Post-marketing reports include nausea, vomiting, and local pain and burning.
The warnings section covers three topics:
- Radiation risk: the agent “contributes to a patient’s overall long-term cumulative radiation exposure.”
- Hypersensitivity: reactions to somatostatin receptor imaging agents have mostly involved the skin, such as rash and itching.
- Image misinterpretation: uptake reflects somatostatin receptor density in tumors, so images need careful reading.
What is gallium Ga 68 dotatate’s regulatory status, and how is it used in research?
NETSPOT is a prescription product in the United States. Drugs@FDA lists its marketing status as prescription, with Novartis as the holder (Drugs@FDA).
In research, gallium Ga 68 dotatate PET serves as an imaging tool in clinical trials. For example, Emory University ran a completed phase 2 study using it in 17 men with metastatic castration resistant prostate cancer (NCT03448458). That is a research use, not an approved indication.
Frequently asked questions about gallium Ga 68 dotatate
Is gallium Ga 68 dotatate a peptide?
Its targeting part is. Dotatate is a cyclic peptide of 8 amino acids attached to a DOTA chelator that holds gallium-68.
Is it a treatment for neuroendocrine tumors?
No. It is a diagnostic imaging agent. Lutathera, which pairs the same peptide with lutetium-177, is approved as a treatment for certain neuroendocrine tumors.
When was NETSPOT approved?
Drugs@FDA lists the original approval of NETSPOT on June 1, 2016.
What does a positive scan mean?
It shows tissue with many somatostatin receptors. The label warns that uptake reflects receptor density, so images need careful reading.
Does it have a boxed warning?
No. Its warnings cover radiation exposure, allergic reactions and image misinterpretation.
What to know now
- Structure: cyclic 8 amino acid peptide plus DOTA chelator plus gallium-68.
- Approval: NETSPOT, June 1, 2016; prescription only.
- Mechanism: binds somatostatin receptors, especially SSTR2, for PET imaging.
- Label: localizing somatostatin receptor positive neuroendocrine tumors in adults and children.
- Evidence: positive in 48 of 50 known tumors in Study A; pooled sensitivity 90.9%.
- Safety: no serious adverse reactions in label studies; radiation and misreading are key warnings.
What we’re watching
Further NETSPOT label revisions on DailyMed, last revised in October 2023. Label changes for the related dotatate products Detectnet and Lutathera. Related guides: lutetium Lu 177 dotatate, octreotide and lutetium Lu 177 vipivotide tetraxetan.